Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Serum Microbiome Analysis as a Tool Towards Targeted Biomarker for Gastric Cancer
31 Pages Posted: 16 Nov 2018More...
Background: Gastric cancer (GC) has been found to be associated with alterations in the composition of microbiome. However, little is known about the composition of blood microbiome in GC patients. Our aim is to characterize blood microbiome in GC patients and evaluate its potential value as biomarkers.
Methods: 71 GC, 6 atypical hyperplasia (AH), 11 chronic gastritis (CG), and 13 healthy controls (HC) were analyzed for serum microbiome. Meanwhile, serum CEA, CA19-9, and CA72-4, were also detected by electrochemiluminescence assay. Finally, we characterized serum bacterial with significant difference, identified microbial markers and constructed GC classifier.
Findings: The structure of serum microbiome in GC was significantly differed from all other groups, and alpha diversity of serum microbial was decreased from HC to GC. Serum microbiome was significantly correlated to TNM stage, lymphatic metastasis, tumor diameter, and invasion depth in GC. Six genus or species were selected as microbial biomarkers for diagnosis analysis, including Acinetobacter, Bacteroides, Sphingomonas, Comamonas, Haemophilus parainfluenzae, and Pseudomonas stutzeri. ROC analysis showed that AUC of six microbial biomarkers combination was 0.867 (95% CI: 0.775-0.931) with a sensitivity 80.3% and specificity 100%. Further analysis revealed that its diagnostic value was better than CEA, CA19-9, CA72-4, alone or in combination. Moreover, the structure of serum microbiota was different in GC metastasis (GC-M) or non-metastasis (GC-NM).
Interpretation: As a pilot investigation to characterize serum microbiome in GC, our study provided a novel strategy for discovering serum microbiota-targeted biomarkers for GC diagnosis.
Funding Statement: National Natural Science Foundation of China (81572070, 81601846, 81401709, 31471202). Natural Science Foundation of Shandong Province (ZR2017MH044). Taishan Scholars Program of Shandong Province (tshw20120206). Key Research and Development Project of Shandong Province (2016GSF201122, 2016GSF201124, 2016YYSP009, 2016GSF201120). The Fundamental Research Funds of Shandong University (2014QLKY03). Science and Technology Development Project in Jinan (201805084). Science Foundation of Qilu Hospital of Shandong University (2015QLQN38, 2015QLMS45). City of Weihai technique extension project (2016GNS023).
Declaration of Interests: The authors declare no conflict of interest.
Ethics Approval Statement: Our study was approved by the Ethics Committee of Qilu Hospital (KYLL-2015-097). The participants signed written informed consents.
Keywords: Gastric Cancer; Serum; Biomarker; Diagnosis; Microbiome
Suggested Citation: Suggested Citation